Multiple myeloma (MM) is a common plasma cell malignancy, accounting for the second largest hematological malignancy. Proteasome inhibitors represented by bortezomib (BTZ) have been the main treatment for patients with newly diagnosed and relapsed or refractory myeloma in nearly two decades. Although BTZ has improved the prognosis of MM patients, MM remains incurable in most patients, mainly because MM cells become resistant to BTZ. This review is to better understand the mechanism of MM resistance to BTZ and explore possible new therapeutic strategies.
题目: 多发性骨髓瘤硼替佐米耐药机制的研究进展.
摘要: .多发性骨髓瘤是一种常见的浆细胞恶性肿瘤，占血液系统恶性肿瘤的第二位。近20年来，以硼替佐米为代表的蛋白酶体抑制剂一直是用于新诊断和复发或难治性骨髓瘤患者的主要治疗手段。虽然硼替佐米改善了多发性骨髓瘤患者的预后，但大多数患者仍然无法被治愈，主要是因为多发性骨髓瘤细胞对硼替佐米产生了耐药性。本综述旨在更好地了解多发性骨髓瘤对硼替佐米的耐药机制，并探讨可能存在的新的治疗策略。.
Keywords: bortezomib; drug resistance; multiple myeloma.